pRb2/p130 localizes to the cytoplasm in diffuse gastric cancer by Cito, L. et al.
pRb2/p130 Localizes to
the Cytoplasm in Diffuse
Gastric Cancer
LETIZIA CITO,1 PAOLA INDOVINA,2,3 IRIS MARIA FORTE,1 FRANCESCA PENTIMALLI,1
DOMENICO DI MARZO,1 PASQUALE SOMMA,4 DANIELA BARONE,1 ANTONELLA PENON,2
DANILA PENON,5 ELISA CECCHERINI,2 PIETRO MICHELI,4 LUCA SARAGONI,6
MARINA DI DOMENICO,3,7 ANTONIA FEOLA,7,8 FRANCO ROVIELLO,9 ELISEO MATTIOLI,2,10
GIOVAN GIACOMO GIORDANO,8y AND ANTONIO GIORDANO1,2,3*
1Oncology Research Center of Mercogliano (CROM), Istituto Nazionale per lo studio e la cura dei tumori “Fondazione Giovanni
Pascale”-IRCCS, Naples, Italy
2Department of Medicine, Surgery and Neuroscience, University of Siena and Istituto Toscano Tumori (ITT), Siena, Italy
3Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Temple University, Philadelphia, Pennsylvania
4Azienda Ospedaliera dei Colli-Pathology section, Naples, Italy
5Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Naples, Italy
6Pathology Division, Morgagni-Pierantoni Hospital, Forlì, Italy
7Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy
8Department of Biology, University Federico II of Naples, Naples, Italy
9Department of Medicine, Surgery and Neuroscience, Unit of Surgical Oncology, University of Siena, Siena, Italy
10Division of Anatomic Pathology, “Madonna delle Grazie” Hospital, Matera, Italy
pRb2/p130 is a key tumor suppressor, whose oncosuppressive activity has mainly been attributed to its ability to negatively regulate cell
cycle by interacting with the E2F4 and E2F5 transcription factors. Indeed, pRb2/p130 has been found altered in various cancer types in
which it functions as a valuable prognostic marker. Here, we analyzed pRb2/p130 expression in gastric cancer tissue samples of diffuse
histotype, in comparison with their normal counterparts. We found a cytoplasmic localization of pRb2/p130 in cancer tissue samples,
whereas, in normal counterparts, we observed the expected nuclear localization. pRb2/p130 cytoplasmic delocalization can lead to cell
cycle deregulation, but considering the emerging involvement of pRb2/p130 in other key cellular processes, it could contribute to gastric
tumorigenesis also through other mechanisms. Our data support the necessity of further investigations to verify the possibility of using
pRb2/p130 as a biomarker or potential therapeutic target for diffuse gastric cancer.
J. Cell. Physiol. 230: 802–805, 2015. © 2014 Wiley Periodicals, Inc.
Gastric cancer is still one of the most frequent causes of cancer
death among women and men (Pinheiro et al., 2014). The most
frequently used gastric cancer classiﬁcation, which is based on
Lauren’s criteria, distinguishes two main groups that differ not
only in morphology but also clinically and epidemiologically: the
intestinal and the diffuse histotypes (Lauren, 1965; Vauhkonen
et al., 2006). The ﬁrst has a glandular morphology and is
characterized by a stepwise progression, whereas gastric
tumors of the diffuse histotype are characterized by an
undifferentiated morphology, the lack of precursor lesions,
occur most commonly in young patients and generally have a
worse prognosis (Nardone, 2003; Vauhkonen et al., 2006;
Chiaravalli et al., 2012; Corso et al., 2012). In the clinical
practice however, regardless of histotype, the clinical stage
seems to be the most important single and independent factor
affecting survival (Vauhkonen et al., 2006). Although various
markers for early diagnosis have been discovered (Guilford
et al., 1998; Shafaghi et al., 2013; Liu et al., 2014), the lack of
remarkable early symptoms still results in a late stage diagnosis.
Therefore, it is a priority to identify new tools for an early
diagnosis.
pRb2/p130 is a member of the Rb family of tumor
suppressors (Giordano et al., 1991; Yeung et al., 1993; Indovina
et al., 2013), whose altered expression and delocalization was
found in various cancers. In particular, reduced expression of
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pRb2/p130 has been found in breast and endometrial (Susini
et al., 1998; Milde-Langosch et al., 2001; Susini et al., 2001),
brain (Li et al., 2004), ovarian (D’Andrilli et al., 2004), lung
(Claudio et al., 2000; Caputi et al., 2002), prostate (Claudio
et al., 2002), salivary gland cancers (Russo et al., 2005), vulvar
squamous cell cancer (Zamparelli et al., 2001), choroidal
(Massaro-Giordano et al., 1999) and oral mucosa melanoma
(Tanaka et al., 2001), and soft tissue sarcomas (Masciullo et al.,
2008). In various instances, reduced expression of pRb2/p130
was shown to inversely correlate to tumor grading and to be a
prognostic factor indicating a poor overall survival.
Interestingly, a cytoplasmic localization, entailing a loss of
function, was found in various tumor types including lymphoma
cell lines (Cinti et al., 2000). Consistently, pRb2/p130 is
normally localized in the nucleus (Baldi et al., 1995, 1996) and
its oncosuppressive activity has mainly been correlated with its
ability to negatively regulate the cell cycle through the
interaction with the E2F4 and E2F5 transcription factors
(Dyson, 1998). This function of pRb2/p130 is regulated through
changes in its phosphorylation status: when
hypophosphorylated, pRb2/p130 binds E2F4 and E2F5
transcription factors, releasing them after phosphorylation
(Giacinti and Giordano, 2006; Sun et al., 2007). Thus, pRb2/
p130 loss of function, independently from causes, could
determine an uncontrolled transcription of E2F4 and E2F5
target genes, which include genes involved in cell cycle
progression (Sardet et al., 1995; Claudio et al., 1996; Takahashi
et al., 2000). Moreover, beyond its function as cell cycle
regulator, pRb2/p130 is also involved in many other cellular
processes, such as regulation of apoptosis, senescence, and
differentiation, which could all contribute to the pRb2/p130
oncosuppressive activity (Indovina et al., 2013).
In 2007, we analyzed the expression of various cell cycle
regulated genes, including pRb2/p130, in gastric cancer and
found that in tumors of the intestinal type, pRb2/p130
cytoplasmic localization correlated with the expression levels
of EZH2, a member of the Polycomb group family of
transcriptional regulators (Matsukawa et al., 2006; Guo et al.,
2014), and VEGF, which both have a recognized role in
gastric carcinogenesis (Chen et al., 2014; Mao et al., 2014).
Here, we focused speciﬁcally on the analysis of pRb2/p130
expression in a wider series of gastric tumors of the diffuse
histotype.
Materials and Methods
Tissue sample collection
Thirty eight tissue samples from patients (15 women and 23 men)
undergone to surgery in 2004 at the Monaldi hospital were
collected. All the patients suffered from gastric cancer of diffuse
histotype. TNM classiﬁcation parameters are the following: nine
samples were classiﬁed as T1 (all of themwereN0), 18 as T2 (9N0,
1 N1, 7 N2, and 1 N3), seven as T3 (3 N1, 3 N2-one of which was
M1- and 1 N3), and ﬁve as T4 (3 N1 and 2 N2).
Immunohistochemistry
Sections of each sample, cut from the same blocks, were used
to perform immuhistochemical reactions, according to the protocol
previouslydescribed inMattioli etal. (2007).Theantibodyanti-pRb2/
p130 (Abcam, code ab17124,mousemonoclonal) was used at a 1:25
dilution and incubated 1 h at room temperature.
Statistical analysis
After checking data normality by the D’Agostino-Pearson
normality test, statistically signiﬁcant differences were evaluated by
the one-way repeated measures Anova with Tukey post-test
(GraphPad Prism Software, version 5.01 for Windows), which is
appropriate to compare the means of multiple matched groups;
P< 0.05 was considered to be statistically signiﬁcant.
Results
pRb2/p130 accumulates in the cytoplasm of
gastric cancer cells
We analyzed pRb2/p130 expression in 38 gastric cancer
samples and their adjacent normal tissues by
immunohistochemical analysis. Results showed a marked
cytoplasmic localization of pRb2/p130 in cancer tissues (Fig. 1),
whereas normal adjacent tissues showed the expected
nuclear localization (Baldi et al., 1995, 1996). In particular, in
non-tumor samples the mean percentage of cells with
pRb2/p130 nuclear staining was signiﬁcantly higher than the
mean percentage of cells with cytoplasmic staining
(73.95% 5.71% vs 26.05% 5.71%, P< 0.001) (Fig. 2).
Conversely, in tumors the mean percentage of cells with
pRb2/p130 nuclear expression was signiﬁcantly lower than
that with cytoplasmic expression (25.00% 8.05% vs
76.05% 8.63%, P< 0.001) (Fig. 2). Consistently, the mean
percentage of cells with nuclear pRb2/p130 was signiﬁcantly
higher in normal cells than in cancer cells (73.95% 5.71% vs
25.00% 8.05%, P< 0.001) and the mean percentage of cells
with cytoplasmic pRb2/p130 was signiﬁcantly lower in normal
cells than in cancer cells (26.05% 5.71% vs 76.05% 8.63%,
P< 0.001).
A relationship between the nuclear and cytoplasmic levels of
pRb2/p130 and tumor size and lymph node involvement was
also investigated but no signiﬁcant correlation was detected
(data not shown).
Our results suggest that pRb2/p130 cytoplasmic localization
could be a possible biomarker of stomach cell transformation,
because of the sharp difference in pRb2/p130 localization
between normal and tumor tissue samples.
Discussion
pRb2/p130 deregulation underlies different neoplasms and it is
now well-established that it represents a crucial factor in the
pathogenesis of multiple cancer types for which it could
function as a diagnostic, prognostic or predictive factor.
Although pRb2/p130 oncosuppressive role has been mainly
attributed to its activity as cell cycle regulator (Paggi and
Giordano, 2001; Cito et al., 2010), it is becoming increasingly
clear that pRb2/p130 could contribute to tumor suppression by
other mechanisms including apoptosis, senescence, and
differentiation (Indovina et al., 2013), which all represent
important antitumoral barriers.
Here, we focused on investigating the expression of
pRb2/p130 in diffuse gastric cancer tissue samples, compared
with adjacent normal tissues. The obtained results clearly
showed a signiﬁcantly prevailing cytoplasmic localization of
pRb2/p130 in neoplastic areas, whereas normal tissue areas
showed the expected prevailing nuclear localization. This is
consistent to what found in other tumors. However, while in
salivary gland tumors, for example, cytoplasmic expression of
pRb2/p130 correlated with tumor grading, with the presence of
metastasis and a with decreased probability of survival (Russo
et al., 2005), here we did not ﬁnd a correlation between tumor
staging and higher percentage of cytoplasm localization. Also,
unfortunately, survival data were not available for our patient
group.
Overall our analysis shows a striking difference between
pRb2/p130 localization in normal and tumor tissues,
suggesting that pRb2/p130 has an important role in gastric
tumorigenesis although its contribution in the development/
progression of gastric cancer needs to be further elucidated
and pRb2/p130 subcellular delocalization could not only
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affect cell cycle regulation but also many other cellular
processes.
In conclusion, we believe that pRb2/p130 cytoplasmic
localization in diffuse histotype gastric cancer deserves further
investigations because it might represent not only a potential
marker for this kind of neoplasm but also a therapeutic target.
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